Cancer
Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua
May 8, 2019Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma
Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
Top Ten most popular articles on Pharmafile.com this week!
April 26, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma
The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
ICR calls for faster access to innovative cancer drugs
April 25, 2019Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing
The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …
Pfizer immune-oncology leader joins Aduro Biotech as new CMO
April 23, 2019Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …
Bowel cancers adjust themselves to hide from immunotherapies
April 15, 2019Sales and Marketing CEA, Cancer, bowel cancer, immunotherapy, oncology, tumour
Bowel cancers can avoid being caught by immunotherapy by ‘switching off’ a molecule on the surface of cells that is …
Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer
April 15, 2019Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma
Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …
Clovis Oncology discontinue phase 2 bladder cancer trial
April 15, 2019Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer
Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer
April 12, 2019Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …
Researchers use CRISPR to reveal gene targets in 30 types of cancer
April 11, 2019Research and Development Cancer, crispr, drug development, genes, genetics, oncology
Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
